20-F: Legend Biotech Reports Full Year 2024 Financial Results, Citing Strong CARVYKTI Sales

Sentiment:

Annual Results 11 March 2025 4:02 PM

Legend Biotech's 20-F filing highlights significant revenue growth driven by CARVYKTI sales, alongside ongoing investments in research and development.

Better than expectedThe company's net losses decreased compared to the previous year.The company's revenue increased compared to the previous year.

Summary

Legend Biotech Corporation reported its full year 2024 financial results, showcasing substantial revenue growth primarily fueled by CARVYKTI sales.
Net trade sales for CARVYKTI reached approximately $965.2 million for the year ended December 31, 2024.
The company's net losses amounted to $177.0 million in 2024, a decrease from $518.3 million in 2023.
Legend Biotech is actively investing in expanding its manufacturing capacity and advancing its pipeline programs.
The company's existing cash and cash equivalents are expected to fund operations into the second quarter of fiscal year 2026.
Legend Biotech is closely monitoring regulatory developments in China and remains committed to complying with applicable laws and regulations.
The company faces potential uncertainty from actions taken by PRC governmental authorities affecting its business in the PRC.
The company is subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. While revenue growth is positive, ongoing losses and risks associated with operations in China and reliance on third parties temper the overall outlook.

Positives

Significant revenue growth driven by CARVYKTI sales.
Net losses decreased compared to the previous year.
Existing cash and cash equivalents are expected to fund operations into the second quarter of fiscal year 2026.
Expanding manufacturing capacity to meet anticipated commercial demand.
Advancing a broad portfolio of autologous CAR-T product candidates targeting various cancers.
Developing allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates for MM and NHL.

Negatives

The company incurred net losses of $177.0 million in 2024.
The company faces potential uncertainty from actions taken by PRC governmental authorities affecting its business in the PRC.
The company is subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations.

Risks

The company is substantially dependent on the commercial success of CARVYKTI.
The company may not be able to successfully establish and maintain manufacturing capabilities and infrastructure to supply its requirements of CARVYKTI and its product candidates.
The commercial success of CARVYKTI will depend upon the degree of market acceptance by physicians, third-party payors and others in the medical community.
The company will need additional funding to complete the development of its product candidates, which may not be available on acceptable terms, if at all.
The company's operating results may be adversely affected by inflation.
The company's business is subject to economic, political, regulatory and other risks associated with international operations.
The company's organizational structure may create significant conflicts of interest.

Future Outlook

The company expects its existing cash and cash equivalents will enable it to fund its operating expenses and capital expenditure requirements for at least the next 12 months and plans to continue to invest in manufacturing capabilities and advance its pipeline programs.

Industry Context

The announcement highlights Legend Biotech's position in the competitive cell therapy landscape, particularly in the treatment of multiple myeloma, and its ongoing efforts to expand its commercial reach and develop new therapies.

Comparison to Industry Standards

The document does not contain enough information to make a detailed comparison to industry standards.
To perform a comparison, more specific details would be needed regarding the company's R&D spending as a percentage of revenue, clinical trial success rates, manufacturing costs, and market share compared to key competitors like Bristol-Myers Squibb (Abecma), Johnson & Johnson (Tecvayli), and others in the CAR-T space.

Related Party Transactions

The company has entered into various related party transactions with Genscript, including a Master Products and Services Agreement, a Probio Exclusive License Agreement, a Government Affairs Service Agreement, a Pay-on-behalf-of Services Agreement, and lease agreements.

Stakeholder Impact

Shareholders: Potential for increased value due to revenue growth and pipeline development, but also risk due to ongoing losses and operational challenges.
Employees: Continued employment opportunities and potential for career growth within the company.
Patients: Access to innovative cell therapies for cancer treatment.
Suppliers: Potential for increased business opportunities as the company expands its operations.

Next Steps

Continue clinical development of cilta-cel in earlier lines of MM treatment.
Advance the development of other pipeline programs.
Expand manufacturing capacity to meet commercial demand.
Seek additional collaboration opportunities.

Key Dates

Date	Description
2017-12-21	Date of the original Collaboration and License Agreement with Janssen Biotech, Inc.
2018-02-28	Date of Amendment No. 1 to the Collaboration and License Agreement.
2018-03-12	Date of Amendment No. 2 to the Collaboration and License Agreement.
2018-12-10	Date of Amendment No. 3 to the Collaboration and License Agreement.
2019-11-30	Date of Amendment No. 5 to the Collaboration and License Agreement.
2020-05-26	Shareholders approved the Third Amended and Restated Memorandum and Articles of Association.
2020-07-01	Date that the last amended DRR took effect.
2020-12-07	Date of Amendment No. 6 to the Collaboration and License Agreement.
2021-07-26	Date of Amendment No. 7 to the Collaboration and License Agreement.
2021-11-11	Date of Amendment No. 8 to the Collaboration and License Agreement.
2022-02-28	CARVYKTI approved by the FDA.
2022-05-25	European Commission granted conditional marketing authorization of CARVYKTI.
2022-07-07	Date of Amendment No. 9 to the Collaboration and License Agreement.
2022-09-26	Japan's Ministry of Health, Labour and Welfare approved CARVYKTI.
2023-01-27	CARTITUDE-4 met its primary endpoint of showing a statistically significant improvement in PFS compared to standard therapy.
2023-04-12	Effective date of the Master Technology Transfer, Manufacturing and Clinical Supply Services Agreement for BCMA CAR-T Product.
2023-11-10	Date of the License Agreement with Novartis Pharma AG.
2024-04	FDA approved CARVYKTI for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
2024-04-22	European Commission also approved CARVYKTI for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy.
2024-08	Cilta-cel received NMPA approval for the treatment of adults with RRMM who previously received treatment with three or more lines of therapy.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.